touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part Two, click here.
Questions
1. What is Gavo-cel and what is its mechanism of action? (00:31-01:37)
2. Could you tell us a little about the dose escalation study you are presenting? (01:37-03:17)
3. What have been the efficacy and safety findings to date? (03:17-07:36)
Disclosures: David Hong has received research (institution) and grant funding (institution) from: AbbVie, Adaptimmune, Aldi-Norte, Amgen, AstraZeneca, Bayer, BMS, Daiichi-Sankyo, Deciphera, Eisai, Erasca, Fate Therapeutics, Genentech, Genmab, Infinity, Kite, Kyowa, Lilly, LOXO, Merck, Medimmune, Mirati, Mologen, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, SeaGen, Takeda, Turning Point Therapeutics, Verstatem and VM Oncology. He has received travel and accommodation expenses from: Bayer, Genmab, AACR, ASCO, SITC and Telperian. He has received consulting, speaker or advisory role fees from: Adaptimmune, Alpha Insights, Acuta, Alkermes, Amgen, Aumbiosciences, Atheneum, Axiom, Barclays, Baxter, Bayer, Boxer Capital, BridgeBio, CDR-life AG, COR2ed, COG, Ecor1, Genentech, Gilead, GLG, Group H, Guidepoint, HCW Precision, Immunogen, Infinity, Janssen, Liberium, Medscape, Numab, Oncologia Brasil, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Seattle Genetics, ST Cube, Takeda, Tavistock, Trieza Therapeutics, Turning Point, WebMD and Ziopharm. He has other ownership interests from: OncoResponse (Founder), Telperian Inc (Advisor).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson
Filmed in coverage of the ESMO 2021 Annual Meeting.
